Skip to content
Adam Torkildson – Lifestyle
Author:
Sobi, Inc.
Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome
September 10, 2026
Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
July 9, 2026